Elbit Imaging große Gewinne möglich? - 500 Beiträge pro Seite
eröffnet am 19.03.14 14:24:31 von
neuester Beitrag 16.07.14 19:48:45 von
neuester Beitrag 16.07.14 19:48:45 von
Beiträge: 7
ID: 1.192.613
ID: 1.192.613
Aufrufe heute: 0
Gesamt: 11.508
Gesamt: 11.508
Aktive User: 0
ISIN: IL0010811169 · WKN: 904217 · Symbol: EMITF
0,8500
USD
0,00 %
0,0000 USD
Letzter Kurs 16.04.24 Nasdaq OTC
Neuigkeiten
Werte aus der Branche Sonstige Technologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7100 | +25,00 | |
| 0,6100 | +12,96 | |
| 61,62 | +10,19 | |
| 10,840 | +9,05 | |
| 2,3300 | +8,37 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 211,00 | -14,57 | |
| 43,40 | -15,73 | |
| 276,00 | -16,24 | |
| 2,2025 | -18,12 | |
| 57,77 | -18,54 |
Feedback
Israel's Gamida Cell gets buyout offer from unnamed drugmaker
Email
Facebook
0
Twitter
0
ADVERTISEMENT
Reuters
12:56 pm, March 18, 2014
JERUSALEM (Reuters) - Israeli developer of stem cell therapies Gamida Cell has received a buyout offer worth hundreds of millions dollars from an unnamed global pharmaceutical company, two shareholders in the company said on Tuesday.
Elbit Medical Technologies, which has a 30.8 percent share in Gamida, said the offer includes a "significant immediate payment and additional future payments totaling hundreds of millions of dollars".
Israel's Globes financial daily reported that the interested buyer was Swiss drugmaker Novartis, though a spokeswoman for Elbit said they were not commenting on the report.
The offer was received on March 7, said Clal Biotechnology Industries, which has about 22 percent of Gamida, in its own statement to the Tel Aviv Stock Exchange.
Gamida said it is developing a pipeline of products to treat a wide range of conditions, including blood cancers and solid tumors. Its StemEx treatment is being tested as part of a transplant regimen for patients with high risk leukemia and lymphoma [ID:nL5N0CY1CL]
The future payments would be conditioned upon meeting milestones in development, registration and sales, Elbit and Clal said.
Other Gamida shareholders include Teva Pharmaceutical Industries, Amgen, Denali Ventures, Auriga Ventures and Israel Healthcare Venture.
Elbit Medical is 90 percent owned by Elbit Imaging.
(Reporting by Ari Rabinovitch)
0
0
ADVERTISEMENT
Reuters
12:56 pm, March 18, 2014
JERUSALEM (Reuters) - Israeli developer of stem cell therapies Gamida Cell has received a buyout offer worth hundreds of millions dollars from an unnamed global pharmaceutical company, two shareholders in the company said on Tuesday.
Elbit Medical Technologies, which has a 30.8 percent share in Gamida, said the offer includes a "significant immediate payment and additional future payments totaling hundreds of millions of dollars".
Israel's Globes financial daily reported that the interested buyer was Swiss drugmaker Novartis, though a spokeswoman for Elbit said they were not commenting on the report.
The offer was received on March 7, said Clal Biotechnology Industries, which has about 22 percent of Gamida, in its own statement to the Tel Aviv Stock Exchange.
Gamida said it is developing a pipeline of products to treat a wide range of conditions, including blood cancers and solid tumors. Its StemEx treatment is being tested as part of a transplant regimen for patients with high risk leukemia and lymphoma [ID:nL5N0CY1CL]
The future payments would be conditioned upon meeting milestones in development, registration and sales, Elbit and Clal said.
Other Gamida shareholders include Teva Pharmaceutical Industries, Amgen, Denali Ventures, Auriga Ventures and Israel Healthcare Venture.
Elbit Medical is 90 percent owned by Elbit Imaging.
(Reporting by Ari Rabinovitch)
Wie geht es hier weiter? Hat jmd. n Plan?
Das Ding scheint am Boden zu liegen... Ab und zu Zuckt das Teil nach oben...
Die Aktie zog letzte Woche wieder leicht Richtung Norden... Mal sehen wie es hier weiter geht diese Woche.
Trading Spotlight
Aktuell über 8% im Plus heute. Die Käufe nehmen zu. Der Kurs scheint sichlangsam zu erholen.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| 0,00 | |
| +0,27 | |
| -0,05 | |
| -2,20 | |
| -3,75 | |
| -0,13 | |
| +1,06 | |
| +0,64 | |
| -2,68 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 173 | ||
| 147 | ||
| 64 | ||
| 54 | ||
| 52 | ||
| 42 | ||
| 37 | ||
| 35 | ||
| 34 | ||
| 31 |
